SSRIs carry an FDA black box warning for increased suicidal thinking and behavior in patients under 25, especially during the first 1–2 months of therapy or after dose changes. Energy and motivation can recover before mood lifts, giving a previously paralyzed patient the capacity to act on suicidal thoughts. Warning signs in this scenario (giving away belongings, goodbye message, social withdrawal) require an immediate, direct suicide risk assessment using a tool such as C-SSRS, with a safety plan, means restriction (firearms, medications), and a clear follow-up. Reassurance, deferring the visit, or telling the family to abruptly stop fluoxetine are all unsafe.
In-depth explanation
Asking directly about suicide does NOT plant the idea — silence does. The standard for adolescents on a new SSRI is weekly follow-up for the first 4 weeks, then biweekly, with explicit family education on warning signs.
Clinical scenario
Scenario A 16-year-old with newly diagnosed MDD has been on fluoxetine 20 mg PO daily for 1 week. The mother calls the clinic: the teen is "more active" but withdrawn, has organized old photos, given a guitar to a friend, and texted "I love you Mom" last night. No prior suicide attempt is documented but the teen has access to the household firearm. The teen is currently at home with the parent and is willing to come to the clinic.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.